Why Is HOTH Stock Up 70% After-Hours Today?

• HT-VA outperformed Danish drug Novo Nordisk’s blockbuster semaglutide drug in key gene expression markers tied to liver fat regulation, the company said.
• The company is now looking to advance the drug in additional preclinical validation studies.

Shares of Hoth Therapeutics, Inc. (HOTH) jumped 70% after-hours on Monday after data from the company’s preclinical trial evaluating its experimental treatment HT-VA showed significant improvements in key genes responsible for fat production and fat metabolism.

The company said that the trial showed statistically significant reduction in genes driving fat production and increased fat metabolism, positioning HT-VA as therapy for metabolic-associated fatty liver disease and obesity.

The company is now looking to advance the drug in additional preclinical validation studies and evaluate clinical development pathways for metabolic and liver diseases, while also exploring strategic partnerships and collaborations to accelerate development.

Study Takeaways

HT-VA outperformed Danish drug Novo Nordisk’s (NVO) blockbuster semaglutide drug in key gene expression markers tied to liver fat regulation, the company said, while adding that it also demonstrated broad metabolic impact at the genetic levels beyond just weight reduction.

"These results demonstrate that GDNF (HT-VA) is not simply reducing fat, but fundamentally reprogramming how the body produces and metabolizes fat at the genetic level. The ability to shut down fat creation while activating fat metabolism differentiates GDNF from existing therapies, including GLP-1 agonists," said CEO Robb Knie.

HT-VA is part of Hoth’s efforts to move beyond its core dermatology and oncology pipeline, which includes candidates aimed at treating atopic dermatitis and mast-cell derived cancers.

How Did Retail Traders React?

On Stocktwits, retail sentiment around HOTH stock jumped from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume remained at ‘high’ levels.

A Stocktwits user expressed optimism for the rally driving the share price past the $1 mark.

HOTH stock has lost 38% of its value over the past 12 months. 

Read More: SYRE Stock Marks Best Session In About 3 Years — Here’s Why

For updates and corrections, email newsroom[at]stocktwits[dot]com.